Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo ...
Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...
EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...
Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...
EYE-103 is under clinical development by Eyebiotech and currently in Phase III for Diabetic Macular Edema. According to GlobalData, Phase III drugs for Diabetic Macular Edema have a 62% phase ...
Macular degeneration is very common and affects an estimated 19.8 million people in the United States. Approximately one in 10 Americans age 50 and older have an early form of the disease and as many ...
Diabetes can lead to complications throughout the body and commonly causes digestive disorders such as gastroparesis (delayed emptying of the stomach). This can lead to stomach problems and pain.
The Israel Defense Forces struck dozens of terror targets across the Gaza Strip Wednesday night and into Thursday, including a strike that killed a Hamas terrorist ...
today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...
Pete Hegseth, President-elect Donald Trump’s nominee for defense secretary, said in his Senate confirmation hearing that the Oct. 7, 2023, Hamas attacks in Israel were the direct result of ...
Patients with a foveal bulge had significantly enhanced visual acuity if they also had resolved diabetic macular edema ... affected spectral domain optical coherence tomography (SD-OCT), had ...
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.